Current Status of Financing and Reimbursement of Trastuzumab (Herceptin^®) for Adjuvant and Advanced Therapy of Breast Cancer in Germany

Abstract

Trastuzumab (Herceptin^®) is a monoclonal antibody treatment option for breast cancer patients costing up to 5-10 times more than state-of-the-art chemotherapy. A significantly improved outcome for defined groups of patients who are HER2/neu-positive was previously shown for advanced/metastatic breast cancer and recently also for adjuvant therapy in several large phase III trials. However, financial limitations of any health system, even in wealthy nations such as Germany, can prevent optimal treatment. The German Social Security Code requires cost-effectiveness of all medical treatment. Financing of off-label pharmaceuticals is strictly limited by law. In contrast to advanced breast cancer for which trastuzumab is licensed, in the adjuvant setting it is restricted to off-label use and could result in a massive financial loss for the health care provider. So, indication and reimbursement for innovative therapies during the interim phase between clinical trials and official approval remain difficult. In this review, the current situation in Germany and the experience with financing and reimbursement of the costs of trastuzumab in the adjuvant and advanced setting as well as the search for financial solutions are described. Dr. med. Volker R. Jacobs, MBA Oberarzt Forschung and Klinikmanagement Frauenklinik der Technischen Universität München Ismaninger Strasse 22, 81675 München, Germany Tel. +49 894140-5425, Fax -4831 E-mail volkerjacobs@hotmail.com Current Status of Financing and Reimbursement of Trastuzumab (Herceptin®) for Adjuvant and Advanced Therapy of Breast Cancer in Germany Volker R. Jacobs Frauenklinik der Technischen Universität München, Germany

Relevance of Health Economics in Breast Cancer Treatment: Integration of Economics in the Management of Breast Cancer at the Clinic Level

“…Based on and derived from this information, cost drivers can preferably be identified, and a cautious and gentile long-term optimization process can be induced towards a care-to-reimbursement adjustment. Over the years a variety of successful projects have evolved among them; optimizing chemotherapy reimbursement with reduction of oncological pharmaceutical costs by over 83% in just 2 years without changing quality of care [26,27,28], comparison of different chemoregimen [29], process analysis to discover mistakes in ordering, cost attribution, documentation, coding and billing for out-patient chemotherapies [30], prospective analysis of cost and reimbursement for participation in clinical trials [31], identification of off-label status for pharmaceuticals which are not reimbursed by statutory healthcare funds [32], analysis of costs and financial risks of expensive breast implants at 90% under-reimbursed in immediate breast reconstruction after mastectomy [33], prospective study of provider's costs of chemotherapy-related complications such as febrile neutropenia [34] and analysis and optimization of their correlating DRG reimbursement [35], prospective calculation of direct medication cost savings by biomarkers for avoiding chemotherapy in breast cancer at medium relapse risk [36], purchase and contract adjustments for reduction of costs of expensive breast ultrasound equipment to actual clinical needs [37], and identifying unexplainable reimbursement differences of mastectomy between prophylactic BRCA1/BRCA2 and breast cancer patients [38]. Even concordance of biomarker test results to Tumor Board decisions and final therapy can result in economic effects which can be used to optimize cost for their application [39].…”

Cross-National Comparison of Medical Costs Shared by Payers and Patients: A Study of Postmenopausal Women with Early-Stage Breast Cancer Based on Assumption Case Scenarios and Reimbursement Fees

“…The unit costs were derived or estimated from various public data sources or published literature in Japan [23,26,27], the UK [28,29,30,31,32], and Germany [33,34,35,36]. Most of the costs were obtained from these sources for 2011 (the UK) or 2012 (Japan and Germany).…”

Chief Medical Clinic Manager of a University OB/GYN Clinic – An Innovative Job Description as Management Response for Increase of Profitability, Quality of Care, and Physicians’ Freedom of Action

“…Innovative non-tariff contracts which can reflect personal effort and engagement offerabetteralternativebutarenotpossibleinavarietyof Germanhospitalsforgeneralstructuralreasons.Thefinancial outcome and potential gains from a variety of previous projectsarelistedintable2.Fromthispreviousexperiencein two German OB/GYN clinics at university level, the return oninvestmentforaclinic-basedCMCMis-dependingonthe economicmaturationoftheinstitution-atleastaminimum ofthreefoldand,asprovenovermanyyears,canberealistically up to ten times the salary over time, making it at the presenttimeanexcellentinvestmentforeconomicimprovementfromwithinaclinicatthelevelofcare. within 2 years [19,20], addressing the problem of expensive innovativepharmacologicalsubstances [21],comparingcosts between different chemo-regimens [22], and finally solving theproblemofunder-reimbursedclinicalstudycosts [23].A monthly report about costs and progress is supporting the target of cost-conscious resource consumption [24,25] …”